Haemopoietic Progenitor Cell Sector Clinical Advisory Group

The Haemopoietic Progenitor Cell (HPC) Sector Clinical Advisory Group provides advice to support the implementation of the National Haemopoietic Progenitor Cell Framework. The framework will ensure future arrangements continue to improve access to HPC transplants for Australians.

Role

The advisory group consists of clinical professionals from the Haemopoietic Progenitor Cell (HCP) sector. They will make recommendations to the Jurisdictional Haemopoietic Progenitor Cell Committee (JHPCC) on future HPC sector reform proposed within the National Haemopoietic Progenitor Cell Framework.

For more information on the roles and responsibilities of the advisory group, see the HPC Sector Clinical Advisory Group Governance resource and Terms of Reference

Members

We appoint members for their expertise in clinical haematology, tissue typing, laboratory accreditation and regulatory frameworks.

Member

Role / Expertise

Position

Dr Neil Everest, (Chair)

Clinical & public health; medicines & biologicals regulation; health technology assessment & reimbursement

Senior Medical Adviser, Technology Assessment and Access Division, Department of Health and Aged Care

Prof Robert Carroll

Clinical Nephrologist & Tissue Typing Specialist

Senior Nephrologist, South Australia Health, SA

Immunogenetics Laboratory Manager, Lifeblood Australian Red Cross Blood Service

Ms Natalie Clark Reynolds

Consumer representative

Consumer representative

Ms Sophy Suy

NATA representative

Lead Accreditation Specialist, National Association of Testing Authorities (NATA) Australia

A/Prof Anna Johnston

Clinical Haematologist and Transplant Physician

Head of Clinical Haematology and Bone Marrow Transplant, Royal Hobart Hospital, TAS

Director, State-wide Bone Marrow Transplant Service, TAS

Prof Ian Kerridge

Clinical Haematologist, Transplant Physician and Bioethicist

Staff Haematologist and Bone Marrow Transplant Physician, Royal North Shore Hospital, NSW

Prof of Bioethics and Medicine, University of Sydney, NSW

Ms Fiona McCormack

TGA representative

Director, In Vitro Diagnostics Medical Device (IVD) Team, Medical Devices Authorisation Branch, Therapeutic Goods Administration, Department of Health and Aged Care

Dr Richard Mitchell

Clinical Haematologist and Oncologist, Paediatric Transplant Physician

Acting Director, Kids Cancer Centre, Sydney Children’s Hospital, NSW

Director of Transplant & Cellular Therapies Unit, Kids Cancer Centre, Sydney Children’s Hospital, NSW

Dr Duncan Purtill

Clinical Haematologist and Transplant Physician

Clinical Haematologist and Director of the Bone Marrow Transplant Program, Fiona Stanley Hospital, WA

Medical Director, Bone Marrow Transplant Laboratory, PathWest Laboratory Medicine, WA

Dr Beverley Rowbotham

Clinical Haematologist and Accreditation Specialist

Consultant Haematologist, Sullivan Nicolaides Pathology, QLD

Chair, National Pathology Accreditation Advisory Council, Department of Health and Aged Care

Prof Erica Wood

Clinical Haematologist

Consultant Haematologist, Monash Health, VIC

Prof and Head, Transfusion Research Unit, Monash University, VIC

A/Prof David Yeung

Clinical Haematologist and Transplant Physician

Head of Haematology, Royal Adelaide and The Queen Elizabeth Hospitals, SA

Consultant Haematologist, Royal Adelaide Hospital and South Australia Pathology, SA

If the Advisory Group requires other expertise, we will invite more clinical and non-clinical experts to participate.

Meetings

The HPC Sector Clinical Advisory Group will meet at least four times per year.

Reports

In May 2023, the HPC Sector Clinical Advisory Group provided its Recommendations on Adult Haemopoietic Progenitor Cell Donor Recruitment Reform to the JHPCC.

This advice:

  • included point-in-time data and references to service providers that currently have a role in HPC donor recruitment
  • outlined what those roles might look like if they were to be maintained.

These recommendations are not intended to direct the roles of service providers in the future, or prejudice future contractual arrangements or procurement activities, which are decisions for all governments based on this advice and other considerations. 

These recommendations are being considered by all governments and, where supported, will be prioritised according to need and available resources.

Contact

HPC Sector Clinical Advisory Group contact

Contact the secretariat for enquiries about the Haemopoietic Progenitor Cell (HPC) Sector Clinical Advisory Group’s work.
Date last updated: